Osteonecrosis of the jaw associated with bisphosphonate therapy in primary osteoporosis.
Keywords:
Osteonecrosis. Osteoporosis. Bisfosfonato. Cirugía oral.Abstract
Purpose: the aim of this review was to study risk factors involved in osteonecrosis of the jaw after oral surgery in patients treated with bisphosphonates because of primary osteoporosis. Methods: in order to find relevant related publications, we conducted a systematic search in specialized (Cochrane Database of Systematic Reviews, Trip Database) and general (Medline, Embase, Isi Web of Knowledge) bibliographic databases. The search strategy included the terms osteonecrosis, adults and oral surgery, and was limited to papers focused in human adults undergoing dentoalveolar surgery while being treated with bisphosphonates because of primary osteoporosis, which had been published in English or Spanish languages between January, 2006 and January, 2012. Systematic reviews, meta-analyses, practice guidelines, randomized clinical trials and case report series were included. Results: 14 papers (case report series) including 43 cases of osteonecrosis of the jaw were selected. Jaw and extraction were the most frequent localization and dental procedure related to the lesions. Mean age of patients was 71, 94 years, being the lesions more frequent among women. Alendronate was the bisphosphonate used in the majority of cases, with a mean duration of treatment before osteonecrosis of the jaw appeared of 48, 25 months. Conclusions: well-designed, prospective and retrospective studies are warranted to evaluate the real weight of each one of those considered as potential risk factors for osteonecrosis of the jaw. Key words: osteonecrosis, osteoporosis, bisphosphonste, oral surgeryDownloads
References
1. NIH Consensus development panel osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-795.
https://doi.org/10.1001/jama.285.6.785
2. MUÑOZ-TORRES M, JÓDAR GIMENO E. Grupo de trabajo de metabolismo mineral óseo de la Sociedad Española de Endocrinología y Nutrición (SEEN). Osteoporosis: informe del grupo de trabajo de metabolismo mineral óseo de la SEEN. Endocrinol Nutr 2007; 54: 53-61.
https://doi.org/10.1016/S1575-0922(07)71405-5
3. PAZIANAS M, MILLER P, BLUMENTALS WA, BERNAL M, KOTHAWALA P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29:1548-1558.
https://doi.org/10.1016/j.clinthera.2007.08.008
4. Division of Reproductive and Urologic Products, Office of New Drugs Division of Pharmacovigilance II, Office of Surveillance and Epidemiology Division of Epidemiology, Office of Surveillance and Epidemiology. Center for Drug Evaluation and Research Food and Drug Administration. Background Document for Meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. Silver Spring, Maryland:FDA, 2011 [acceso 29 de octubre de 2012] Disponible en: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/DrugSafetyandRiskManagementAdvisoryCommittee/ucm270958.pdf
5. RUGGIERO SL, DODSON TB, ASSAEL LA, LANDESBERG R, MARX RE, MEHROTRA B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. J Oral Maxillofac Surg 2009; 67 (5 Suppl.):2-12.
https://doi.org/10.1016/j.joms.2009.01.009
6. MARX RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117.
https://doi.org/10.1016/S0278-2391(03)00720-1
7. RUGGIERO SL, MEHROTRA B, ROSENBERGTJ, ENGROFF SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534.
https://doi.org/10.1016/j.joms.2004.02.004
8. SOSA HENRÍQUEZ M, GÓMEZ DE TEJADA ROMERO MJ, BAGÁN SEBASTIÁN JV, DÍAZ M, DÍEZ PÉREZ A, JODAR GIMENO E et al. Osteonecrosis de los maxilares: documento de consenso de la sociedad española de investigación ósea y del metabolismo mineral (SEIOMM). Rev Osteoporos Metab Miner 2009; 1: 41-51.
9. JUNQUERA LM, MARTÍN-GRANIZO R. Diagnóstico, prevención y tratamiento de la osteonecrosis de los maxilares por bisfosfonatos. Recomendaciones de la sociedad Española de Cirugía Oral y Maxilofacial (SECOM). Rev Esp Cir Oral y Maxilofac 2008; 30: 145-156.
https://doi.org/10.4321/S1130-05582008000300001
10. KHOSLA S, BURR D, CAULEY J, DEMPSTER DW, EBELING FR, FELSENBERG D, GAGEL RS et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479-1491.
https://doi.org/10.1359/jbmr.0707onj
11. MAVROKOKKI T, CHENG A, STEIN B, GOSS A. Nature and frecuency of bisphosphonate-associated osteonecrosis of the jaw in Australia. J Oral Maxillofac Surg 2007; 65: 415-423.
https://doi.org/10.1016/j.joms.2006.10.061
12. BAGÁN J, BLADE J, COZAR JM, CONSTELA M, GARCÍA-SANZ R, GÓMEZ-VEIGA F et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal 2007; 12: E 336-340.
13. KHAN AA, SÁNDOR GKB, DORE E, MORRISON AD, ASAHLI M, AMIN F et al. Canadian consensus practice guidelines for Biphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008; 35: 1391-1397.
14. EDWARDS BJ, HELLSTEIN JW, JACOBSEN PL, KALTMAN S, MARIOTTI A, MIGLIORATI CA. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2008; 139: 1674-1677.
https://doi.org/10.14219/jada.archive.2008.0110
15. Centre for Oral Health Strategy. Prevention of osteonecrosis of the jaw (ONJ) in patients on bisphosphonate therapies. [Internet] Sydney; Centre for Oral HealthStrategy [Elaborado en julio 2010/ consultado enero 2012] Disponible en: http://www.health.nsw.gov.au/policies/gl/2010/pdf/GL2010_010.pdf
16. CARDONA F, BAGÁN JV, SÁINZ E, FIGUERIDO J, GINER F, VIDÁN FJ. Osteonecrosis de los maxilares por bisfosfonatos. Actualización y puesta al día. An Sist Sanit Navar 2009; 32: 413-421.
https://doi.org/10.4321/S1137-66272009000500012
17. MANTEROLA C, ZAVANDO D. Grupo MINCIR. Cómo interpretar los "niveles de evidencia" en los diferentes escenarios clínicos. Rev Chilena de Cirugía 2009; 61:582-595.
https://doi.org/10.4067/S0718-40262009000600017
18. HARPER RP, FUNG E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 2007; 65: 573-580.
https://doi.org/10.1016/j.joms.2006.10.076
19. KUMAR SKS, MERU MC, SEDGHIZADEH PP. Osteonecrosis of the jaws secondary to bisphosphonate therapy: a case series. J Contemp Dent Pract 2008; 9: 63-69.
https://doi.org/10.5005/jcdp-9-1-63
20. FANTASIA JE. Bisphosphonates-what the dentist needs to know: practical considerations. J Oral Maxillofac Surg 2009; 67 (5 Suppl): 53-60.
https://doi.org/10.1016/j.joms.2009.01.011
21. KUNCHUR R, NEED A, HUGHES T, GOSS A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67: 1167-1173.
https://doi.org/10.1016/j.joms.2009.02.004
22. ALONS K, KUIJPERS SC, DE JONG E, VAN MERKESTEYN JP. Treating low- and medium-potency bisphosphonate-related osteonecrosis of the jaws with a protocol for the treatment of chronic suppurative osteomyelitis: report of 7 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 107:e1-7.
https://doi.org/10.1016/j.tripleo.2008.09.021
23. YAMAGUCHI K, OIZUMI T, FUNAYAMA H, KAWAMURA H, SUGAWARA S. Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale. J Oral Maxillofac Surg 2010; 68: 889-897.
https://doi.org/10.1016/j.joms.2009.04.048
24. DANNEMANN C, GRATZ KW, RIENER MO, ZWAHLEN RA. Jaw osteonecrosis related to bisphosphonate therapy: A severe secondary disorder. Bone 2007; 40: 828-834.
https://doi.org/10.1016/j.bone.2006.11.023
25. HUTCHINSON M, O'RYAN F, CHAVEZ V, LATHON PV, SANCHEZ G, HATCHER DC et al. Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg 2010; 68: 2232-2240.
https://doi.org/10.1016/j.joms.2010.05.003
26. KWON YD, KIM DY, OHE JY, YOO JY, WALTER C. Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67: 2644-2648.
https://doi.org/10.1016/j.joms.2009.04.067
27. SUBRAMANIAN G, COHEN HV, QUEK SYP. A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 112: 744-753.
https://doi.org/10.1016/j.tripleo.2011.04.020
28. TREISTER NS, FRIEDLAND B, WOO SB. Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109: 753-764.
https://doi.org/10.1016/j.tripleo.2009.12.005
29. NARONGROEKNAWIN P, DANILA MI, HUMPHREYS LG, BARASCH A, CURTIS JR. Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. Spec Care Dentist 2010; 30: 77-82.
https://doi.org/10.1111/j.1754-4505.2009.00128.x
30. BEDOGNI A, BETTINI G, TOTOLA A, SAIA G, NOCINI PF. Oral bisphosphonate-associated osteonecrosis of the jaw after implant surgery: a case report and literature review. J Oral Maxillofac Surg 2010; 68: 1662-1666.
https://doi.org/10.1016/j.joms.2010.02.037
31. GOSS A, BARTOLD M, SAMBROOK P, HAWKER P. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: a south australian case series. J Oral Maxillofac Surg 2010; 68: 337-343.
https://doi.org/10.1016/j.joms.2009.09.037
32. MONTERO M, CALABUIG E, MUÑOZ ML, VALERO JL, TODOLÍ J, CALABUIG JR et al. Densitometría axial y periférica en el diagnóstico de la osteoporosis. Reemo 2002; 11: 140-143.
33. GONZÁLEZ MACÍAS J, RIANCHO MORAL J. Osteoporosis. Concepto. Epidemiología. Etiología. Manifestaciones clínicas y complicaciones. Medicine 2006; 9: 3873-3879.
https://doi.org/10.1016/S0211-3449(06)74345-4
34. GROVA MARCO MV, GARCÍA SANTANA S, MIRAVALLE PESCADOR A, GONZÁLEZ RODRÍGUEZ E, GONZÁLEZ PADILLA E, SOSA HENRÍQUEZ M. Enfermedades metabólicas óseas. Introducción. Remodelado óseo y pérdida ósea. Osteoporosis: concepto, epidemiología, morbilidad y mortalidad. Repercusiones económicas de la osteoporosis. Enfermedad infradiagnosticada. Medicine 2010; 10: 4109-4116.
https://doi.org/10.1016/S0304-5412(10)70170-0
35. CARBONELL C, DÍEZ A, CALAF J, CALOTO MT, NOCEA G, LARA N. Pauta de tratamiento inicial en pacientes con osteoporosis: uso de antirresortivos y suplementos farmacológicos (calcio y vitamina D) en la práctica clínica. Reumatol Clin 2012; 8: 3-9.
https://doi.org/10.1016/j.reuma.2011.07.006
36. Alendronate, etidronato, risedronato, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women.[Internet]. London. NICE. 2005 [Elaborado en 2008/ consultado en mayo de 2012]. Technology Appraisal Guidance 161. Disponible en: http://www.nice.org.uk/TA161
37. PALASKA PK, CARTSOS V, ZAVRAS AI. Bisphosphonates and time to osteonecrosis developement. Oncologist 2009; 14: 1154-1166.
https://doi.org/10.1634/theoncologist.2009-0115
38. BLACK DM, DELMAS PD, EASTELL R, REID IR, BOONEN S, CAULEY JA et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822.
https://doi.org/10.1056/NEJMoa067312
39. BLACK DM, SCHWARTZ AV, ENSRUD KE, CAULEY JA, LEVIS S, QUANDT SA et al. Effects of continuing or stopping alendronate after 5 years of treatment. The fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 2006; 296: 2927-2938.
https://doi.org/10.1001/jama.296.24.2927
40. CARDONA TORTAJADA F, SAINZ GÓMEZ E, GINER MUÑOZ F, FIGUERIDO GARMENDIA J. Osteonecrosis de los maxilares por bisfosfonatos orales. Presentación de 3 casos. Aten Primaria 2012; 44: 116-117.
https://doi.org/10.1016/j.aprim.2010.12.013
41. KAPLAN I, ANAVI K, ANAVI Y, CALDERON S, SCHWARTZ-ARAD D, TEICHER S et al. The clinical spectrum of Actinomyces-associated lesions of the oral mucosa and jawbones: correlations with histomorphometric analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108: 738-746.
https://doi.org/10.1016/j.tripleo.2009.06.019
42. NAIK NH, RUSSO TA. Bisphosphonate-related osteonecrosis of the jaw: the role of Actinomyces. Clin Infect Dis 2009; 49: 1729-1732.
https://doi.org/10.1086/648075
43. LEE CYS, PIEN FD, SUZUKI JB. Identification and treatment of bisphosphonate-associated actinomycotic osteonecrosis of the jaws. Implant Dentistry 2011; 20: 331-336.
https://doi.org/10.1097/ID.0b013e3182310f03
44. HANSEN T, KUNKEL M, SPRINGER E, WALTER C, WEBER A, SIEGEL E et al. Actinomycosis of the jaws-histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 2007; 451: 1009-1017.
https://doi.org/10.1007/s00428-007-0516-2
45. KOS M, BRUSCO D, KUEBLER J, ENGELKE W. Clinical comparison of patients with osteonecrosis of the jaws, with and without a history of bisphosphonates administration. Int J Oral Maxillofac Surg 2010; 39: 1097-1102.
https://doi.org/10.1016/j.ijom.2010.04.054
46. MARX RE, CILLO JE JR, ULLOA JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397-2410.
https://doi.org/10.1016/j.joms.2007.08.003
47. LAZAROVICI TS, MESILATY-GROSS S, VERED I, PARIENTE C, KANETY H, GIVOL N et al. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg 2010; 68: 2241-2247.
https://doi.org/10.1016/j.joms.2010.05.043
48. American Society for Bone and Mineral Research Task Force on Osteonecrosis of the Jaw. KHOSLA S, BURR D, CAULEY J, DEMPSTER DW, EBELING PR, FELSENBERG D et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2008; 66: 1320-1321.
https://doi.org/10.1016/j.joms.2008.01.054
49. LEE CYS, SUZUKI JB. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: A prospective clinical study. Implant Dentistry 2010; 19:29-38.
https://doi.org/10.1097/ID.0b013e3181cec8bc
50. SOSA HENRÍQUEZ M, DÍEZ PÉREZ A. La hormona paratiroidea en el tratamiento de la osteoporosis. An Med Interna 2007; 24: 87-97.
https://doi.org/10.4321/S0212-71992007000200010
51. GLIKLICH R, WILSON J. Epidemiology of bisphosphonate-related osteonecrosis of the jaws: The utility of a national registry. J Oral Maxillofac Surg 2009; 67: 71-74.
https://doi.org/10.1016/j.joms.2009.01.005
52. RIBAS-DEIX O, SANZ-GALLÉN P, NOGUÉ S. Osteonecrosis de la mandíbula asociada al tratamiento oral con ibandronato. An Sist Sanit Navar 2011; 34: 489-491.
Published
How to Cite
Issue
Section
License
Copyright (c) 2013 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
